A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours

被引：0

作者：

de Bono, J. S. ^{[1
,2
]}

Lord, S. ^{[3
]}

Yap, C. ^{[4
]}

Miranda, S. ^{[5
]}

Veal, G. J. ^{[6
]}

Chandran, K. ^{[7
]}

Paschalis, A. ^{[8
]}

Peron, C. ^{[9
]}

Rekowski, J. ^{[10
]}

Gurel, B. ^{[5
]}

Paisley, D. ^{[11
]}

McGuigan, L. ^{[12
]}

Ingram, P. J. ^{[13
]}

Kwek, K. Y. ^{[14
]}

Halbert, G. ^{[12
]}

Westwood, N. B. ^{[12
]}

Griffin, A. E. ^{[11
]}

Kostaras, L. ^{[11
]}

Boyd-Kirkup, J. D. ^{[15
]}

Walter, H. S. ^{[11
]}

机构：

[1] Inst Canc Res, Prostate Canc Targeted Therapies Grp, Sutton, England

[2] Royal Marsden Hosp, Sutton, England

[3] Univ Oxford, Dept Oncol, Oxford, England

[4] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England

[5] ICR Inst Canc Res, Clin Studies Canc Biomarkers, London, England

[6] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne, England

[7] Royal Marsden Hosp NHS Fdn, Prostate Canc Targeted Therapies Grp, Sutton, England

[8] ICR Inst Canc Res, Clin Studies, London, England

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England

[10] ICR Inst Canc Res, Clin Trials & Stat Unit, London, England

[11] CRUK Canc Res UK, Ctr Drug Dev, London, England

[12] Canc Res UK, Ctr Drug Dev, London, England

[13] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Singapore, Singapore

[14] Hummingbird Biosci, Clin Dev, Singapore, Singapore

[15] Hummingbird Biosci Pte Ltd Temasek Lifesci Labs, Res, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1873

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

687P

引用

页码：S479 / S480

页数：2

共 50 条

[21] A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Krauss, J.
Eigentler, T.
Schreiber, J.
Weishaupt, C.
Terheyden, P.
Heinzerling, L.
Mohr, P.
Weide, B.
Ochsenreither, S.
Gutzmer, R.
Becker, J. C.
Kiecker, F.
Funkner, F.
Heidenreich, R.
Kays, S-K.
Klinkhardt, U.
Gnad-Vogt, U. S.
Scheel, B.
Schoenborn-Kellenberger, O.
Seibel, T.
ANNALS OF ONCOLOGY, 2019, 30 : 191 - +
[22] Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
Deng, Ting
Liu, Zhigang
Han, Zhengquan
Zhou, Huan
Liu, Rui
Li, Yijing
Li, Shaorong
Xiu, Peng
Wang, Shuni
Zhang, Yiping
Ba, Yi
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[23] A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense
A. Atmaca
C. Pauligk
K. Steinmetz
F. Marmé
G. M. Haag
M. Rieger
O. G. Ottmann
P. Ruf
H. Lindhofer
S.-E. Al-Batran
BMC Cancer, 16
[24] Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
Li, H.
Xu, J.
Shao, B.
Liu, R.
Ran, R.
Song, G.
Jiang, H.
Wang, K.
Shi, Y.
Liu, J.
Hu, W.
Chen, F.
Zhang, G.
Wang, Y.
Zhao, C.
Ru, J.
Wang, Q.
Rugo, H. S.
Li, G.
ANNALS OF ONCOLOGY, 2019, 30
[25] First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
Pegram, Mark D.
Hamilton, Erika P.
Tan, Antoinette R.
Storniolo, Anna Maria
Balic, Kemal
Rosenbaum, Anton, I
Liang, Meina
He, Peng
Marshall, Shannon
Scheuber, Anita
Das, Mayukh
Patel, Manish R.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (08) : 1442 - 1453
[26] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Banerji, Udai
van Herpen, Carla M. L.
Saura, Cristina
Thistiethwaite, Fiona
Lord, Simon
Moreno, Victor
Macpherson, Iain R.
Boni, Valentina
Rolfo, Christian
de Vries, Elisabeth G. E.
Rottey, Sylvie
Geenen, Jilt
Eskens, Ferry
Gil-Martin, Marta
Mommers, Ellen C.
Koper, Norbert P.
Aftimos, Philippe
LANCET ONCOLOGY, 2019, 20 (08): : 1124 - 1135
[27] A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.
Meulendijks, Didier
Lolkema, Martijn P. J. K.
Voest, Emile E.
De Jonge, Maja J.
Sleijfer, Stefan
Schellens, Jan H. M.
Fleitas, Tania
Cervantes-Ruiperez, Andres
Martinez-Garcia, Maria
Taus, Alvaro
Soerensen, Morten Mau
Thomas, Marlene
Meneses-Lorente, Georgina
Adessi, Celine
Di Scala, Lilla
Keelara, Abiraj
Jacob, Wolfgang
Weisser, Martin
Lassen, Ulrik Niels
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
Eskens, F.
Opdam, F.
Gort, E.
Gelderblom, H.
Prestegarden, L.
Pico-Navarro, C.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
[29] A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
Haense, N.
Atmaca, A.
Pauligk, C.
Steinmetz, K.
Marme, F.
Haag, G. M.
Rieger, M.
Ottmann, O. G.
Ruf, P.
Lindhofer, H.
Al-Batran, S. -E.
BMC CANCER, 2016, 16
[30] Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
Strickler, John H.
LoRusso, Patricia
Salgia, Ravi
Kang, Yoon-Koo
Yen, Chia Jui
Lin, Chia-Chi
Ansell, Peter
Motwani, Monica
Wong, Shekman
Yue, Huibin
Wang, Lan
Reilly, Edward
Afar, Daniel
Naumovski, Louie
Ramanathan, Ramesh K.
MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1210 - 1217

← 1 2 3 4 5 →